Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2007

Open Access 01-12-2007 | Research

Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells

Authors: Katia Margiotti, Latif A Wafa, Helen Cheng, Giuseppe Novelli, Colleen C Nelson, Paul S Rennie

Published in: Molecular Cancer | Issue 1/2007

Login to get access

Abstract

Background

The androgen receptor is a ligand-induced transcriptional factor, which plays an important role in normal development of the prostate as well as in the progression of prostate cancer to a hormone refractory state. We previously reported the identification of a novel AR coactivator protein, L-dopa decarboxylase (DDC), which can act at the cytoplasmic level to enhance AR activity. We have also shown that DDC is a neuroendocrine (NE) marker of prostate cancer and that its expression is increased after hormone-ablation therapy and progression to androgen independence. In the present study, we generated tetracycline-inducible LNCaP-DDC prostate cancer stable cells to identify DDC downstream target genes by oligonucleotide microarray analysis.

Results

Comparison of induced DDC overexpressing cells versus non-induced control cell lines revealed a number of changes in the expression of androgen-regulated transcripts encoding proteins with a variety of molecular functions, including signal transduction, binding and catalytic activities. There were a total of 35 differentially expressed genes, 25 up-regulated and 10 down-regulated, in the DDC overexpressing cell line. In particular, we found a well-known androgen induced gene, TMEPAI, which wasup-regulated in DDC overexpressing cells, supporting its known co-activation function. In addition, DDC also further augmented the transcriptional repression function of AR for a subset of androgen-repressed genes. Changes in cellular gene transcription detected by microarray analysis were confirmed for selected genes by quantitative real-time RT-PCR.

Conclusion

Taken together, our results provide evidence for linking DDC action with AR signaling, which may be important for orchestrating molecular changes responsible for prostate cancer progression.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55 (1): 10-30.CrossRefPubMed
2.
Klotz L: Hormone therapy for patients with prostate carcinoma. Cancer. 2000, 88 (12 Suppl): 3009-3014. 10.1002/1097-0142(20000615)88:12+<3009::AID-CNCR17>3.0.CO;2-ECrossRefPubMed
3.
Long RJ, Roberts KP, Wilson MJ, Ercole CJ, Pryor JL: Prostate cancer: a clinical and basic science review. J Androl. 1997, 18 (1): 15-20.PubMed
4.
Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001, 1 (1): 34-45. 10.1038/35094009CrossRefPubMed
5.
Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J: Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol. 1999, 69: 307-313. 10.1016/S0960-0760(99)00049-7CrossRefPubMed
6.
Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B: The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol. 1999, 19 (9): 6085-6097.PubMedCentralPubMed
7.
McKenna NJ, O'Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002, 108 (4): 465-474. 10.1016/S0092-8674(02)00641-4CrossRefPubMed
8.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004, 10 (1): 33-39. 10.1038/nm972CrossRefPubMed
9.
Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997, 57 (2): 314-319.PubMed
10.
Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A. 1998, 95 (13): 7379-7384. 10.1073/pnas.95.13.7379PubMedCentralCrossRefPubMed
11.
Janne OA, Moilanen AM, Poukka H, Rouleau N, Karvonen U, Kotaja N, Hakli M, Palvimo JJ: Androgen-receptor-interacting nuclear proteins. Biochem Soc Trans. 2000, 28 (4): 401-405.CrossRefPubMed
12.
Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY: Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene. 2003, 22 (5): 734-739. 10.1038/sj.onc.1206121CrossRefPubMed
13.
Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C: Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem. 1999, 274 (12): 8316-8321. 10.1074/jbc.274.12.8316CrossRefPubMed
14.
Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61 (11): 4315-4319.PubMed
15.
Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ: p300 in prostate cancer proliferation and progression. Cancer Res. 2003, 63 (22): 7638-7640.PubMed
16.
Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z: The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol. 2003, 162 (1): 233-241.PubMedCentralCrossRefPubMed
17.
Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005, 23 (32): 8253-8261. 10.1200/JCO.2005.03.4777CrossRefPubMed
18.
Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS: Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J. 2003, 375 (Pt 2): 373-383. 10.1042/BJ20030689PubMedCentralCrossRefPubMed
19.
Berry MD, Juorio AV, Li XM, Boulton AA: Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res. 1996, 21 (9): 1075-1087. 10.1007/BF02532418CrossRefPubMed
20.
Craig SP, Thai AL, Weber M, Craig IW: Localisation of the gene for human aromatic L-amino acid decarboxylase (DDC) to chromosome 7p13-->p11 by in situ hybridisation. Cytogenet Cell Genet. 1992, 61 (2): 114-116.CrossRefPubMed
21.
Zhu MY, Juorio AV: Aromatic L-amino acid decarboxylase: biological characterization and functional role. Gen Pharmacol. 1995, 26 (4): 681-696. 10.1016/0306-3623(94)00223-ACrossRefPubMed
22.
Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS: Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol. 2007, 38 (1): 161-170. 10.1016/j.humpath.2006.07.003CrossRefPubMed
23.
Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995, 270 (5235): 467-470. 10.1126/science.270.5235.467CrossRefPubMed
24.
Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, Greenberger LM, Frost P, Bai W, Zhang Y: Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology. 2004, 145 (8): 3913-3924. 10.1210/en.2004-0311CrossRefPubMed
25.
Zhang Y, Akinmade D, Hamburger AW: The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription. Nucleic Acids Res. 2005, 33 (18): 6024-6033. 10.1093/nar/gki903PubMedCentralCrossRefPubMed
26.
Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, Shih HM, Shi XB, Devere White RW, Chen HW, Tepper CG, Kung HJ: Male Germ Cell-Associated Kinase, a Male-Specific Kinase Regulated by Androgen, Is a Coactivator of Androgen Receptor in Prostate Cancer Cells. Cancer Res. 2006, 66 (17): 8439-8447. 10.1158/0008-5472.CAN-06-1636CrossRefPubMed
27.
Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ: Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006, 66 (22): 11039-11046. 10.1158/0008-5472.CAN-06-2442CrossRefPubMed
28.
Beisvag V, Junge FK, Bergum H, Jolsum L, Lydersen S, Gunther CC, Ramampiaro H, Langaas M, Sandvik AK, Laegreid A: GeneTools--application for functional annotation and statistical hypothesis testing. BMC Bioinformatics. 2006, 7: 470- 10.1186/1471-2105-7-470PubMedCentralCrossRefPubMed
29.
30.
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990, 347 (6289): 146-151. 10.1038/347146a0CrossRefPubMed
31.
Xu LL, Shanmugam N, Segawa T, Sesterhenn IA, McLeod DG, Moul JW, Srivastava S: A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics. 2000, 66 (3): 257-263. 10.1006/geno.2000.6214CrossRefPubMed
32.
Rae FK, Hooper JD, Nicol DL, Clements JA: Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Mol Carcinog. 2001, 32 (1): 44-53. 10.1002/mc.1063CrossRefPubMed
33.
Wang M, Kim IG, Steinert PM, McBride OW: Assignment of the human transglutaminase 2 (TGM2) and transglutaminase 3 (TGM3) genes to chromosome 20q11.2. Genomics. 1994, 23 (3): 721-722. 10.1006/geno.1994.1571CrossRefPubMed
34.
Dubbink HJ, Verkaik NS, Faber PW, Trapman J, Schroder FH, Romijn JC: Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J. 1996, 315 ( Pt 3): 901-908.CrossRef
35.
Haag P, Bektic J, Bartsch G, Klocker H, Eder IE: Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol. 2005, 96 (3-4): 251-258. 10.1016/j.jsbmb.2005.04.029CrossRefPubMed
36.
Geppert M, Archer BT, Sudhof TC: Synaptotagmin II. A novel differentially distributed form of synaptotagmin. J Biol Chem. 1991, 266 (21): 13548-13552.PubMed
37.
Lania AG, Mantovani G, Spada A: Mechanisms of disease: Mutations of G proteins and G-protein-coupled receptors in endocrine diseases. Nat Clin Pract Endocrinol Metab. 2006, 2 (12): 681-693. 10.1038/ncpendmet0324CrossRefPubMed
38.
Hollmann MW, Strumper D, Herroeder S, Durieux ME: Receptors, G proteins, and their interactions. Anesthesiology. 2005, 103 (5): 1066-1078. 10.1097/00000542-200511000-00022CrossRefPubMed
39.
Perez DM, Karnik SS: Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev. 2005, 57 (2): 147-161. 10.1124/pr.57.2.2CrossRefPubMed
40.
Daaka Y: G proteins in cancer: the prostate cancer paradigm. Sci STKE. 2004, 2004 (216): re2-PubMed
41.
Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA: Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003, 169 (3): 1143-1149. 10.1097/01.ju.0000042162.08938.27CrossRefPubMed
42.
Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y: Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 2003, 63 (9): 2037-2041.PubMed
43.
Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A, Daaka Y: Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int J Cancer. 2002, 102 (6): 572-579. 10.1002/ijc.10734CrossRefPubMed
44.
Sivashanmugam P, Tang L, Daaka Y: Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem. 2004, 279 (20): 21154-21159. 10.1074/jbc.M313776200CrossRefPubMed
45.
Porter AT, F ACRO, Ben-Josef E: Humoral mechanisms in prostate cancer: A role for FSH. Urol Oncol. 2001, 6 (4): 131-138. 10.1016/S1078-1439(00)00124-1.CrossRefPubMed
46.
Nambi P, Aiyar N: G protein-coupled receptors in drug discovery. Assay Drug Dev Technol. 2003, 1 (2): 305-310. 10.1089/15406580360545116CrossRefPubMed
47.
Civelli O, Bunzow JR, Grandy DK: Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol. 1993, 33: 281-307. 10.1146/annurev.pa.33.040193.001433CrossRefPubMed
48.
Gingrich JA, Caron MG: Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 1993, 16: 299-321. 10.1146/annurev.ne.16.030193.001503CrossRefPubMed
49.
Sidhu A, Niznik HB: Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci. 2000, 18 (7): 669-677. 10.1016/S0736-5748(00)00033-2CrossRefPubMed
50.
Zanassi P, Paolillo M, Feliciello A, Avvedimento EV, Gallo V, Schinelli S: cAMP-dependent protein kinase induces cAMP-response element-binding protein phosphorylation via an intracellular calcium release/ERK-dependent pathway in striatal neurons. J Biol Chem. 2001, 276 (15): 11487-11495. 10.1074/jbc.M007631200CrossRefPubMed
51.
Yan Z, Feng J, Fienberg AA, Greengard P: D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proc Natl Acad Sci U S A. 1999, 96 (20): 11607-11612. 10.1073/pnas.96.20.11607PubMedCentralCrossRefPubMed
52.
Sadar MD, Hussain M, Bruchovsky N: Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer. 1999, 6 (4): 487-502. 10.1677/erc.0.0060487CrossRefPubMed
53.
Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem. 2002, 277 (32): 29304-29314. 10.1074/jbc.M204131200CrossRefPubMed
Metadata
Title
Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells
Authors
Katia Margiotti
Latif A Wafa
Helen Cheng
Giuseppe Novelli
Colleen C Nelson
Paul S Rennie
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-6-38

Other articles of this Issue 1/2007

Molecular Cancer 1/2007 Go to the issue

Review

Contribution of oncoproteomics to cancer biomarker discovery

Research

MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2

Research

Enhancing the anti-angiogenic action of histone deacetylase inhibitors

Hypothesis

Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors

Review

Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications

Research

High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits